<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855281</url>
  </required_header>
  <id_info>
    <org_study_id>WI_16-233</org_study_id>
    <nct_id>NCT02855281</nct_id>
  </id_info>
  <brief_title>Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer</brief_title>
  <official_title>Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wissenschaftliches Institut Bethanien e.V</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Pathology, University Clinic DÃ¼sseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wissenschaftliches Institut Bethanien e.V</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective diagnostic pilot study to create hypotheses regarding
      immunocytochemistry (ICC) PD-L1 analysis of pleural effusions in NSCLC patients as compared
      to the reference standard of PD-L1 immunohistochemistry (IHC). This comparison will be done
      to assess sensitivity and specificity of PD-L1 detection by ICC in pleural effusions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PD-L1 prevalence IHC</measure>
    <time_frame>At baseline</time_frame>
    <description>Number/prevalence of PD-L1-positive patients according to immunohistochemistry (IHC) of pleural biopsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD-L1 prevalence ICC</measure>
    <time_frame>At baseline</time_frame>
    <description>Number/prevalence of PD-L1-positive patients according to immunocytochemistry (ICC) of pleural aspirate</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>NSCLC with pleural effusion</arm_group_label>
    <description>The population for selection of potential study participants is comprised of clinical routine patients presenting with (suspected malignant) pleural effusion. These patients must have an indication for pleural puncture. The cause and nature of the pleural effusion at this time point will be unknown in many cases. To establish this, further diagnostic procedures are required. Only patients with confirmed diagnosis of non-small cell lung cancer will be included in the data analysis.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The population for selection of potential study participants is comprised of clinical
        routine patients presenting with (suspected malignant) pleural effusion. These patients
        must have an indication for pleural puncture. The cause and nature of the pleural effusion
        at this time point will be unknown in many cases. To establish this, further diagnostic
        procedures are required. Only patients with confirmed diagnosis of non-small cell lung
        cancer will be included in the data analysis.

        A patient in whom suspicion of pleural manifestation of lung cancer is not confirmed, will
        be considered a screening failure and thus excluded from the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of malignant pleural effusion with indication for pleural puncture and
             thoracoscopy

          -  Confirmed diagnosis of non-small cell lung cancer according to ERS guidelines

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnancy and/or lactation

          -  Acute and life-threatening illness (instable angina pectoris, acute pulmonary arterial
             embolism, myocardial infarction, etc.)

          -  Any contraindication to undergo thoracoscopy (e.g. anticoagulation therapy which
             cannot be discontinued for the procedure)

          -  Any medical, psychological or other condition impairing the patient's ability to
             provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winfried J Randerath, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wissenschaftliches Institut Bethanien e.V</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcel Treml, Dr.</last_name>
    <phone>+49212636661</phone>
    <email>marcel.treml@klinik-bethanien.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wissenschaftliches Institut Bethanien e. V.</name>
      <address>
        <city>Solingen</city>
        <state>NRW</state>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winfried J Randerath, Prof. Dr.</last_name>
      <phone>+49-212-63-6660</phone>
      <email>institut@klinik-bethanien.de</email>
    </contact>
    <investigator>
      <last_name>Winfried J Randerath, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

